Literature DB >> 17635742

Venous thrombosis in the elderly.

F R Rosendaal1, A VAN Hylckama Vlieg, C J M Doggen.   

Abstract

While the overall incidence of venous thrombosis is 1-2 per 1000 per year, it is close to 1% per year in the very old. The case-fatality rate of thrombosis is high in the elderly, particularly among those with cancer. The risk of major hemorrhage during anticoagulant treatment is also strongly age-dependent, contributing to the vulnerability of the old patient with thrombosis. From this perspective it is surprising that far fewer studies into the etiology and treatment of venous thrombosis have focused on the elderly than on young and middle-aged patients. In this review we discuss that, while environmental risk factors, such as immobilization and cancer, are important causes of thrombosis in the elderly, abnormalities of the coagulation system are equally, or even more, important than in young individuals. In addition to a review of the literature, new data are presented from the MEGA-study. Thrombosis in the elderly should be a focus of future studies.

Entities:  

Mesh:

Year:  2007        PMID: 17635742     DOI: 10.1111/j.1538-7836.2007.02489.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  25 in total

1.  High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?

Authors:  Anja J M Schreijer; Pieter H Reitsma; Suzanne C Cannegieter
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

2.  Factor V Leiden, prothrombin 20210G>A, MTHFR 677C>T and 1298A>C, and homocysteinemia in Tunisian blood donors.

Authors:  Samira Hadhri; Mohamed Ben Rejab; Hajer Guedria; Lamia Ifa; Noureddine Chatti; Hadef Skouri
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

3.  Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.

Authors:  Waltraud Leiss; Marie Méan; Andreas Limacher; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Joseph Osterwalder; Beat Frauchiger; Christian M Matter; Nils Kucher; Anne Angelillo-Scherrer; Jacques Cornuz; Martin Banyai; Bernhard Lämmle; Marc Husmann; Michael Egloff; Markus Aschwanden; Nicolas Rodondi; Drahomir Aujesky
Journal:  J Gen Intern Med       Date:  2014-08-21       Impact factor: 5.128

4.  Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study.

Authors:  Leocadio Rodríguez-Mañas; Ricardo Gómez-Huelgas; Fernando Veiga-Fernández; Gema Monteagudo Ruiz; Javier Martínez González
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 5.  Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures.

Authors:  Heinrich Wolfgang Thaler; Peter Dovjak; Bernhard Iglseder; Georg Pinter; Ernst Müller; Walter Müller; Katharina Pils; Peter Mikosch; Inge Gerstorfer; Michaela Zmaritz; Monique Weissenberger-Leduc; Markus Gosch
Journal:  Wien Med Wochenschr       Date:  2013-09-04

6.  New insights into the mechanisms of venous thrombosis.

Authors:  Nigel Mackman
Journal:  J Clin Invest       Date:  2012-07-02       Impact factor: 14.808

7.  The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology.

Authors:  Marie Méan; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Beat Frauchiger; Joseph Osterwalder; Nils Kucher; Bernhard Lämmle; Jacques Cornuz; Anne Angelillo-Scherrer; Nicolas Rodondi; Andreas Limacher; Sven Trelle; Christian M Matter; Marc Husmann; Martin Banyai; Markus Aschwanden; Michael Egloff; Lucia Mazzolai; Olivier Hugli; Henri Bounameaux; Drahomir Aujesky
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

8.  The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study.

Authors:  Kristine Blix; Sigrid K Brækkan; Saskia le Cessie; Finn E Skjeldestad; Suzanne C Cannegieter; John-Bjarne Hansen
Journal:  Eur J Epidemiol       Date:  2014-04-19       Impact factor: 8.082

9.  Coagulation activation in autoimmune bullous diseases.

Authors:  A V Marzano; A Tedeschi; D Spinelli; D Fanoni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

10.  Investigation of age-adjusted D-dimer using an uncommon assay.

Authors:  Christopher Parks; Richard Bounds; Barbara Davis; Richard Caplan; Tom Laughery; Eli Zeserson
Journal:  Am J Emerg Med       Date:  2018-09-27       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.